Paiola, M., Portnoy, D. M., Hao, L. Y., Bukhari, S., Winchester, R. J., Henick, B. S., Mor, A., & Gartshteyn, Y. (2025). Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells. Journal for ImmunoTherapy of Cancer, 13(3), e010758. https://doi.org/10.1136/jitc-2024-010758

Henick, B. S., Koch, P. D., Gainor, J. F., Awad, M. M., Chiuzan, C., Izard, S., Georgis, Y., Mallick, S., Garofano, R. F., Wong, C. V., Saqi, A., Grindheim, J., Schulze, K., Sonett, J. R., Rizvi, N. A., Izar, B., Taylor, A. M., & Shu, C. A. (2024). Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. Journal for ImmunoTherapy of Cancer, 12(12), e009301. https://doi.org/10.1136/jitc-2024-009301

Maynard, R., Fitzgerald, A., Nasir, A., Eisman, S. E., Jablonski, S. A., Pearson, G., Mace, E., & Weiner, L. M. (2024). 1123 Promoting immune cell tumor invasion through forced overexpression of proteases. Regular and Young Investigator Award Abstracts, A1245–A1245. https://doi.org/10.1136/jitc-2024-sitc2024.1123

Saenger, Y., Zhang, C., Espinoza, G., Bracero, Y., Kenchappa, D., Moon, J.-Y., Matteo, A., Bioh, L., Sultana, S., Singh, A., Aung, T., Gartrell, R. D., Leung, L., Ferringer, T., Chang, R., Horst, B., Nastiuk, K., Rimm, D., & Geskin, L. (2024). 127 Digital pathology prognostic biomarkers- time for clinical application in melanoma. Regular and Young Investigator Award Abstracts, A140–A141. https://doi.org/10.1136/jitc-2024-sitc2024.0127

Schoenfeld, A. J., Izar, B., Spira, A., Zamarin, D., Spigel, D. R., Hoimes, C., McDermott, D. F., Sehgal, K., Najjar, Y. G., Garon, E. B., Sullivan, R. J., Henick, B., Leal, T. A., Hurwitz, M., McKay, R., Gong, X., Rokade, S., Stager, A. M., Bach, K., … Oft, M. (2024). 1325 T cell and immune activation from a phase 1 study of STK-012, a first-in-class IL-2R α/β selective partial agonist in advanced solid tumors. Regular and Young Investigator Award Abstracts, A1484–A1484. https://doi.org/10.1136/jitc-2024-sitc2024.1325

Mallick, S., Henick, B., Georgis, Y., Zhakula, N., Concepcion-Crisol, C., Herzberg, B., & Taylor, A. (2024). 1365 Chromosome 19p status associates with clinical outcomes in a histology-dependent manner in non-small cell lung cancer. Regular and Young Investigator Award Abstracts, A1529–A1529. https://doi.org/10.1136/jitc-2024-sitc2024.1365

Sommerhalder, D., Demel, K., Noel, M. S., Emamekhoo, H., Peguero, J., Balaraman, R., Moy, R. H., Scheuber, A., Haas, J., Chabas, D., Kumar, P., Daigle, S. R., Dasen, S., Zhang, X., Gutierrez, M., Sharma, S., & Hussain, A. (2024). 682 Ongoing phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: clinical safety update and renal cell carcinoma (RCC) efficacy analysis. Regular and Young Investigator Award Abstracts, A782–A783. https://doi.org/10.1136/jitc-2024-sitc2024.0682

Davar, D., Williams, A., Lopez, J., Olson, D., Sato, T., Shaw, H., Friedman, C. F., Thistlethwaite, F., Middleton, M., Lebbe, C., Ma, V. T., Izar, B., Lau, P., Bechter, O., Kirk, P., Yuan, Y., Marshall, S., & Hamid, O. (2024). 694 Phase 1 safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM). Regular and Young Investigator Award Abstracts, A796–A796. https://doi.org/10.1136/jitc-2024-sitc2024.0694

Sharma, M. R., Johnson, M. L., Puzanov, I., Sznol, M., Mckean, M., Gainor, J. F., Spira, A., Henick, B., Tolcher, A. W., Chen, C. T., El-Khoueiry, A., Broderick, J., Peng, L., Che, J., Cao, L., Wilson, D., Lathers, D., Horak, C., Feltquate, D., & Luke, J. J. (2024). 758 GLIMMER-01: phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors. Regular and Young Investigator Award Abstracts, A862–A862. https://doi.org/10.1136/jitc-2024-sitc2024.0758

Ager, C. R., Jugler, C., Zhu, Y., Chen, D., Athar, M., Izar, B., Bickers, D., & Kim, A. (2024). 791 Immunological correlates of response to vismodegib and PD-1 blockade in an autochthonous model of basal cell nevus (Gorlin-Goltz) syndrome. Regular and Young Investigator Award Abstracts, A896–A896. https://doi.org/10.1136/jitc-2024-sitc2024.0791

Daigle, S. R., Elliott, G., Boiko, S., Sommerhalder, D., Noel, M. S., Sharma, S., Balaraman, R., Gutierrez, M., Demel, K., Moy, R. H., Ciccone, D., Zhang, X., Scheuber, A., & Kumar, P. (2024). 83 Tumor immune microenvironment characterization from pre- and post-dose tumors collected from a phase 1/2 study of NDI-101150, a hematopoietic progenitor kinase 1 (HPK1) inhibitor. Regular and Young Investigator Award Abstracts, A91–A91. https://doi.org/10.1136/jitc-2024-sitc2024.0083

Iwamoto, F., Rotolo, J. A., Abbate, F., Scuoppo, C., Levrero, C., Buerki, R. a, Dalahmah, O. A., & Haras, A. V. (2024). 991 ST101, an inhibitor of the transcription factor C/EBPß, promotes an immune-active tumor microenvironment in a window of opportunity (WoO) study of patients with glioblastoma (GBM). Regular and Young Investigator Award Abstracts, A1111–A1112. https://doi.org/10.1136/jitc-2024-sitc2024.0991

Atkins, M. B., Jegede, O. A., Haas, N. B., Mcdermott, D. F., Bilen, M. A., Stein, M., Sosman, J., Alter, R., Plimack, E. R., Ornstein, M. C., Hurwitz, M., Peace, D. J., Einstein, D., Catalano, P. J., Hammers, H., & Regan, M. M. (2024). Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal for ImmunoTherapy of Cancer, 12(4), e008293. https://doi.org/10.1136/jitc-2023-008293

Hu, X., Bukhari, S. M., Tymm, C., Adam, K., Lerrer, S., Henick, B. S., Winchester, R. J., & Mor, A. (2024). Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity. Journal for ImmunoTherapy of Cancer, 12(3), e008482. https://doi.org/10.1136/jitc-2023-008482

Daugherty, B. L., Boohaker, R. J., Johnstone, R., Stinson, K., Zhao, G., Zang, M., Qian, J., Wang, T. C., & Lederman, S. (2023). 1345 mTFF2-MSA (mTNX-1700) suppresses tumor growth and increases survival in anti-PD-1 treated CT26.wt subcutaneous and CT26-Luciferase orthotopic syngeneic colorectal cancer models by targeting MDSCs. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.1345

Ventin, M., Cattaneo, G., Jia, J., Arya, S., Maggs, L., Sun, Y., Boland, G. M., Jenkins, R. W., Ksander, B. R., Haq, R., Wang, X., Ryeom, S., Ferrone, C. R., & Ferrone, S. (2023). 317 B7-H3-targeted CAR T cell with an inducible caspase 9 suicide gene effectively eradicates uveal melanoma liver metastases. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0317

Qian, J., Ryeom, S., Daugherty, B. L., Lederman, S., & Wang, T. C. (2023). 481 A CXCR4 partial agonist TFF2-MSA sensitized advanced gastric cancer to PD-1 blockade by systematically reducing PMN-MDSC accumulation, immunosuppression, and generation in bone marrow. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0481

Minns, H., Padilla, O., Wei, H.-J., Gartrell, R. D., Webster-Carrion, A., Tazhibi, M., McQuillan, N., Zhang, X., Gallitto, M., Yeh, R., Zhang, Z., Hei, T., Szalontay, L., Pavisic, J., Garty, G., Garvin, J., Canoll, P., Vanpouille-Box, C., Menon, V., … Wu, C.-C. (2023). 53 Inducing immune response with FLASH and conventional radiation in diffuse midline glioma (DMG). Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0053

Stein, M. N., Hawley, J., Zibelman, M., Pachynski, R., Dreicer, R., Zarrabi, K. K., Miles, B., Hauke, R. J., Marshall, M. A., Jones, B., Wheeler, V., Sebastian, S., Anderson, K., Vardeu, A., Davis, C., Bendall, J., & Shore, N. (2023). 665 Immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer: A clinical trial in progress. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0665

Malki, M. A., Keyzner, A., Suh, H. C., Matin, A., Buonomo, E., Wang, Y., Abelowitz, N., Murray, J., MacBeath, G., Barton, D., Chattopadhyay, S., & Reshef, R. (2023). 682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0682

Bupathi, M., Wang, J. S., Hu-Lieskovan, S., Piha-Paul, S. A., Chmielowski, B., Garmezy, B., Najjar, Y. G., Stein, M. N., Yao, L., Kanodia, J., Clynes, R., McGovern, P., & Thompson, B. (2023). 764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0764

Migden, M. R., Chai-Ho, W., Daniels, G. A., Wise-Draper, T. M., Kheterpal, M., Tang, J. C., Bolotin, D., Verschraegen, C., Poklepovic, A. S., Khan, S. A., Ibrahim, S. F., Zeitouni, N. C., Medina, T., Tsai, K. K., Tucci, C., Navia, S., Donthireddy, L., Bommareddy, P. K., Hou, J. W., & Davar, D. (2023). 777 Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ and hematopoietic cell transplant recipients with advanced cutaneous malignancies (ARTACUS). Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0777

Patel, S. P., Carvajal, R., Montazeri, K., Reddy, S., Lutzky, J., Khan, S. A., Chmielowski, B., Bhatia, S., Medina, T., Haymaker, C., Sheth, R., Kuban, J. D., Thornton, L., Wehrenberg-Klee, E., Novelli, P., Lucci, A., Sarli, V., Meas, S., Cox, B., … Davar, D. (2023). 1534 Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial. Late-Breaking Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.1534

Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., Luke, J. J., Mitchell, T. C., Mooradian, M. J., Rubin, K. M., Salama, A. K., Shirai, K., Taube, J. M., Tawbi, H. A., Tolley, J. K., … Sullivan, R. J. (2023). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. Journal for ImmunoTherapy of Cancer, 11(10), e006947. https://doi.org/10.1136/jitc-2023-006947

Ager, C. R., Zhang, M., Chaimowitz, M., Bansal, S., Tagore, S., Obradovic, A., Jugler, C., Rogava, M., Melms, J. C., McCann, P., Spina, C., Drake, C. G., Dallos, M. C., & Izar, B. (2023). KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response. Journal for ImmunoTherapy of Cancer, 11(9), e006782. https://doi.org/10.1136/jitc-2023-006782

Siddiqui, B. A., Chapin, B. F., Jindal, S., Duan, F., Basu, S., Yadav, S. S., Gu, A.-D., Espejo, A. B., Kinder, M., Pettaway, C. A., Ward, J. F., Tidwell, R. S. S., Troncoso, P., Corn, P. G., Logothetis, C. J., Knoblauch, R., Hutnick, N., Gottardis, M., Drake, C. G., … Subudhi, S. K. (2023). Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). Journal for ImmunoTherapy of Cancer, 11(3), e006262. https://doi.org/10.1136/jitc-2022-006262

Joshi, M., Tuanquin, L., Zhu, J., Walter, V., Schell, T., Kaag, M., Kilari, D., Liao, J., Holder, S. L., Emamekhoo, H., Sankin, A., Merrill, S., Zheng, H., Warrick, J., Hauke, R., Gartrel, B., Stein, M., Drabick, J., Degraff, D. J., & Zakharia, Y. (2023). Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. Journal for ImmunoTherapy of Cancer, 11(2), e006551. https://doi.org/10.1136/jitc-2022-006551

Tanagala, K. K. K., Morin-Baxter, J., Carvajal, R., Cheema, M., Dubey, S., Nakagawa, H., Yoon, A., Cheng, Y.-S. L., Taylor, A., Nickerson, J., Mintz, A., & Momen-Heravi, F. (2022). SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response. Journal for ImmunoTherapy of Cancer, 10(12), e005088. https://doi.org/10.1136/jitc-2022-005088

Gupta, P., Dang, M., Hao, D., Bojja, K., Tran, T., Shehwana, H., Kamiya-Matsuoka, C., Li, J., Audia, A., Kassab, C., Ott, M., Gumin, J., Alenazy, S., Goldman, A., Seth, S., Maheshwari, A., Balasubramaniyan, V., Vaillant, B., Groot, J. de, … Bhat, K. (2022). 1001 Immunophenotyping of brain tumors identifies interferon enriched phagocytes in human gliomas. Regular and Young Investigator Award Abstracts, A1043–A1043. https://doi.org/10.1136/jitc-2022-sitc2022.1001

Maynard, R., Fitzgerald, A., Nasir, A., Glasgow, E., Jablonski, S., Veken, P. V. D., Pearson, G., Mace, E., & Weiner, L. (2022). 1012 Fibroblast activation protein regulates human natural killer cell migration. Regular and Young Investigator Award Abstracts, A1055–A1055. https://doi.org/10.1136/jitc-2022-sitc2022.1012

Friedman, C., Carvajal, R., Davar, D., Castanon, E., Ascierto, P., Calvo, E., O’Hara, M., Powell, S., Shapira-Frommer, R., Garralda, E., Renouf, D. J., Perets, R., Yunan, M., Ravindran, P., Hammell, A., O’Brien, S., Xu, K., Wilson, N., Jhatakia, A., … Gutierrez, M. (2022). 592 Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: part 1 results. Regular and Young Investigator Award Abstracts, A620–A621. https://doi.org/10.1136/jitc-2022-sitc2022.0592

Liao, C.-Y., Johnson, B., Spira, A., Carbone, D., Henick, B., Overman, M., Polite, B., Roychowdhury, S., Mahipal, A., Ahn, D., Johnson, M., Schenk, D., Bae, K., Davis, M., Jooss, K., Ferguson, A., & Solomon, B. (2022). 660 Clinicopathologic characteristics of patients with metastatic colorectal cancer with molecular responses following treatment with an individualized neoantigen vaccine regimen. Regular and Young Investigator Award Abstracts, A691–A691. https://doi.org/10.1136/jitc-2022-sitc2022.0660

Stein, M., Goodman, O., Dorff, T., Narayan, V., Avitia, J., McKay, R., Nordquist, L., Rettig, M., Schweizer, M., Thomas, R., Silverman, M., Yao, L., Clynes, R., & Shorr, J. (2022). 668 A phase 2 study of vudalimab, a PD-1 x CTLA-4 bispecific antibody, plus chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer. Regular and Young Investigator Award Abstracts, A698–A698. https://doi.org/10.1136/jitc-2022-sitc2022.0668

Hou, J., Goodman, O., Berz, D., Yao, L., & Soni, N. (2022). 733 A phase 2 study of vudalimab (XmAb®20717), an anti-PD-1/CTLA-4 bispecific antibody, in patients with selected gynecological malignancies and high-risk metastatic castration-resistant prostate-cancer. Regular and Young Investigator Award Abstracts, A765–A765. https://doi.org/10.1136/jitc-2022-sitc2022.0733

Sharma, M., Lathers, D., Johnson, M., Luke, J., Puzanov, I., Curti, B., Chen, C., El-Khoueiry, A., Henick, B., Callahan, M., Sznol, M., Patel, S., Wilson, D., Ricker, M., Cao, L., Jayaraman, P., Che, J., Peng, L., Feltquate, D., … Tolcher, A. (2022). 772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01). Regular and Young Investigator Award Abstracts, A803–A803. https://doi.org/10.1136/jitc-2022-sitc2022.0772

Hamid, O., Chiappori, A. A., Thompson, J. A., Doi, T., Hu-Lieskovan, S., Eskens, F. A. L. M., Ros, W., Diab, A., Spano, J.-P., Rizvi, N. A., Wasser, J. S., Angevin, E., Ott, P. A., Forgie, A., Yang, W., Guo, C., Chou, J., & El-Khoueiry, A. B. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 10(10), e005471. https://doi.org/10.1136/jitc-2022-005471

Dercle, L., McGale, J., Sun, S., Marabelle, A., Yeh, R., Deutsch, E., Mokrane, F.-Z., Farwell, M., Ammari, S., Schoder, H., Zhao, B., & Schwartz, L. H. (2022). Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy. Journal for ImmunoTherapy of Cancer, 10(9), e005292. https://doi.org/10.1136/jitc-2022-005292

Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A., Sikic, B. I., Rahma, O., Cho, D. C., Rizvi, N. A., Sznol, M., Lutzky, J., Bauman, J. E., Bitting, R. L., Starodub, A., Jimeno, A., Reardon, D. A., Kaley, T., Iwamoto, F., Baehring, J. M., Subramaniam, D. S., … Keler, T. (2022). Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. Journal for ImmunoTherapy of Cancer, 10(8), e005147. https://doi.org/10.1136/jitc-2022-005147

Henick, B. S., Villarroel-Espindola, F., Datar, I., Sanmamed, M. F., Yu, J., Desai, S., Li, A., Aguirre-Ducler, A., Syrigos, K., Rimm, D. L., Chen, L., Herbst, R. S., & Schalper, K. A. (2022). Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer, 10(7), e005025. https://doi.org/10.1136/jitc-2022-005025

de Vries, E. G., & Schwartz, L. H. (2022). Perspectives on imaging and immunotherapy: a review series. Journal for ImmunoTherapy of Cancer, 10(6), e005006. https://doi.org/10.1136/jitc-2022-005006

Govindan, R., Aggarwal, C., Antonia, S. J., Davies, M., Dubinett, S. M., Ferris, A., Forde, P. M., Garon, E. B., Goldberg, S. B., Hassan, R., Hellmann, M. D., Hirsch, F. R., Johnson, M. L., Malik, S., Morgensztern, D., Neal, J. W., Patel, J. D., Rimm, D. L., Sagorsky, S., … Herbst, R. S. (2022). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. Journal for ImmunoTherapy of Cancer, 10(5), e003956. https://doi.org/10.1136/jitc-2021-003956

Schöffski, P., Tan, D. S. W., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R. D., Kyi, C., Esaki, T., Prawira, A., Akerley, W., De Braud, F., Hui, R., Zhang, T., Soo, R. A., Maur, M., Weickhardt, A., Krauss, J., Deschler-Baier, B., Lau, A., … Hong, D. S. (2022). Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for ImmunoTherapy of Cancer, 10(2), e003776. https://doi.org/10.1136/jitc-2021-003776

He, X., Zhou, S., Dolan, M., Shi, Y., Wang, J., Quinn, B., Jahagirdar, D., Huang, W.-C., Tsuji, M., Pili, R., Ito, F., Ortega, J., Abrams, S. I., Ebos, J. M. L., & Lovell, J. F. (2021). Immunization with short peptide particles reveals a functional CD8+T-cell neoepitope in a murine renal carcinoma model. Journal for ImmunoTherapy of Cancer, 9(12), e003101. https://doi.org/10.1136/jitc-2021-003101